WHO ending hydroxycholorquine trial for COVID

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus.

Berlin: The World Health Organization says it is ending a trial into whether anti-malarial drug hydroxychloroquine helps patients hospitalised with COVID-19.

WHO said Saturday it has accepted the recommendation from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.

The agency adds that while there was no solid evidence of increased mortality for hospitalized patients given the drugs, there were some associated safety signals in the clinical laboratory findings of an associated trial.

WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterwards.

(With inputs from AP)